[Necrotizing myopathies].
Kumamoto
T
T
Third Department of Internal Medicine, Oita Medical University.
D000208:Acute Disease; D015119:Aminocaproic Acid / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D002994:Clofibrate / Q000009:adverse effects / Q000031:analogs & derivatives; D003937:Diagnosis, Differential; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects; D000960:Hypolipidemic Agents / Q000009:adverse effects; D009135:Muscular Diseases / Q000139:chemically induced / Q000473:pathology; D009336:Necrosis; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects; D011379:Prognosis; D011782:Quadriplegia / Q000139:chemically induced; D013256:Steroids
D000893:Anti-Inflammatory Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D003473:Neuromuscular Nondepolarizing Agents; D013256:Steroids; D002994:Clofibrate; D015119:Aminocaproic Acid